Related Experiment Videos
Role of STAT3 in ischemic preconditioning
1Cardiovascular Research Center, University of Connecticut School of Medicine, Farmington, CT 06030-1110, USA.
Journal of Molecular and Cellular Cardiology
|November 16, 2001
Summary
Ischemic preconditioning (IPC) activates the JAK/STAT pathway, specifically STAT3, to protect the heart. Inhibiting this pathway blocks IPC
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Signal Transduction
Background:
- Ischemic preconditioning (IPC) involves short ischemia/reperfusion episodes that protect the heart.
- Protein tyrosine kinases, MAP kinases, Janus kinase (JAK), and signal transducers and activators of transcription (STATs) are involved in myocardial ischemia/reperfusion.
- Early phase of IPC's role in JAK/STAT signaling is not fully understood.
Purpose of the Study:
- To investigate the role of the JAK/STAT signaling pathway in the early phase of ischemic preconditioning (IPC).
- To determine if JAK/STAT activation mediates the cardioprotective effects of IPC.
Main Methods:
- Isolated working rat hearts were used.
- Hearts were perfused with or without a JAK kinase inhibitor (AG490).
- Hearts underwent IPC, followed by global ischemia and reperfusion.
Main Results:
- IPC led to significant phosphorylation of JAK2 and STAT3, which was blocked by AG490.
- IPC demonstrated cardioprotection, evidenced by improved contractile recovery, reduced infarct size, and fewer apoptotic cardiomyocytes.
- AG490 abolished IPC-mediated cardioprotection, altering survival signals by downregulating Bcl-2 and upregulating Bax.
Conclusions:
- The early phase of IPC activates the JAK/STAT signaling pathway, particularly STAT3.
- STAT3 activation transmits a crucial survival signal to the myocardium during IPC.
- Targeting the JAK/STAT pathway may offer novel therapeutic strategies for myocardial protection.